Analysis: Seeking Balance in the Hyperactive Mental Health Tech Market
The prevalence of mental and behavioral health conditions has been on the rise in recent decades, further aggravated by the pandemic in the last two […]
The prevalence of mental and behavioral health conditions has been on the rise in recent decades, further aggravated by the pandemic in the last two […]
The area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is the case, how broadly these therapies can […]
What You Should Know: – Pear Therapeutics, Inc. (Nasdaq: PEAR), announced it has acquired two new digital therapeutic assets that it intends to integrate into […]
Pear Therapeutics has completed its merger with blank cheque company Thimble Point Acquisition Corp, claiming a Nasdaq listing and raising $175 million in gross proceeds […]
Digital health company Pear Therapeutics has won FDA breakthrough device status for reSET-A, its development-stage prescription digital therapeutic (DTx) for people with alcohol-use disorder. The […]
The company got a breakthrough device designation for its app-based program for alcohol use disorder, reset-A. Pear currently has FDA-cleared digital therapeutics to address opioid […]
A real-world study of digital therapeutic (DTx) for opioid use disorder has found that patient show used it had 46% fewer hospital stays than a […]
The digital therapeutics market has unsurprisingly exploded in the past year. Available virtually, digital therapies are developed by clinicians & scientists and are rigorously tested, […]
On Episode 218 of Health in 2 Point 00, it’s a big week in digital health for IPOs. Today Jess asks me about Bicycle Health’s […]
A third US state has agreed to fund Pear Therapeutics’ digital therapeutics (DTx) to treat people with substance and opioid use disorders. The company has […]
EtectRx, which makes wireless sensors embedded in medications, struck a partner with Pear Therapeutics. The companies hope to build products together combining medication adherence data […]
The 3rd generation pharmaceuticals- Digital therapeutics- have become a much-discussed aspect of MedTech today, as they compete with established drug-based pharmaceutical and biotech products to […]
SoftBank’s second Vision Fund led the recent funding round. Pear plans to use it to accelerate reimbursement coverage for its three FDA-cleared products.
What You Should Know: – Pear Therapeutics today announced that it has successfully closed an $80 million Series D financing led by SoftBank Vision Fund […]
Eli Lilly and Incyte Receive FDA’s EUA for Baricitinib + Remdesivir to Treat Hospitalized Patients with COVID-19 Published: Nov 20,2020 | Tags: baricitinib, COVID-19, Eli […]
Shots: Pear Therapeutics launches Somryst as the first PDT intended for use in the treatment of patients with chronic insomnia aged > 22yrs. It addresses […]
After receiving FDA clearance in March, Pear began marketing its prescription digital therapeutic for insomnia. It’s available by prescription only.
There isn’t enough evidence to suggest that digital therapies for people with opioid use disorder (OUD) can improve on standard interventions, according to the Institute […]
The recent decades have shown an accelerated development and evolution in the technology world, leading to unexpected growth in digital health companies. The Digital Therapeutics […]
Copyright © 2024 | WordPress Theme by MH Themes